Lutris Pharma

Anticancer Therapy for Patients Treated with EGFR Inhibitors

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in December 2015, Lutris Pharma operates with 1–10 employees. The company has raised over $40.69 million across four funding rounds from six investors. In January 2025, Lutris Pharma secured funding with Columbus Venture Partners and Pontifax.

Business overview

Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting side effects. The company develops proprietary small molecules, such as the topical B-Raf inhibitor LUT014, to allow patients to continue epidermal growth factor receptor (EGFR) inhibitor treatments without interruptions caused by typical skin toxicities. Leveraging the paradoxical effect of B-Raf inhibitors, LUT014 aims to decrease dermal toxicities and reduce acneiform lesions associated with EGFR inhibitors. Lutris Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical industry.

Strategic signal

Lutris Pharma completed enrollment in its Phase 2 trial of LUT014 in October 2024, evaluating its efficacy for treating EGFR inhibitor-induced acneiform rash in metastatic colorectal cancer patients. This milestone indicates significant progress in the clinical development of their lead product, signaling to investors a clear advancement towards potential market entry and addressing a critical unmet need in oncology patient care.

Log in to access full profile

Company Intelligence Q&A

What is Lutris Pharma's primary focus?
Lutris Pharma is a clinical-stage biopharmaceutical company focused on developing therapies to reduce cutaneous side effects associated with EGFR inhibitors, thereby improving anticancer treatment effectiveness and patient quality of life.
What is LUT014?
LUT014 is a proprietary topical B-Raf inhibitor developed by Lutris Pharma. It is designed to decrease dermal toxicities and reduce acneiform lesions caused by EGFR inhibitors in cancer patients.
When did Lutris Pharma complete enrollment for its Phase 2 trial of LUT014?
Lutris Pharma completed enrollment in its Phase 2 trial of LUT014 for the treatment of EGFR inhibitor-induced acneiform rash in patients with metastatic colorectal cancer in October 2024.
Did Lutris Pharma receive any grants for wound healing development?
In October 2022, Lutris Pharma's Founder and Chairman of the Board received a grant from the California Institute of Regenerative Medicine (CIRM) to develop LUT017 for wound healing.
When did Lutris Pharma raise its most recent funding round?
In January 2025, Lutris Pharma raised funding from investors including.
Log in to access full profile